1.Braunwald E: Heart disease. 1988.
2.Cosselman KE, Navas-Acien A, Kaufman JDJNRC: Environmental factors in cardiovascular disease. 2015, 12:627.
3.Poirier P, Eckel RHJCar: Obesity and cardiovascular disease. 2002, 4:448–453.
4.Mattu HS, Randeva HSJJoe: Role of adipokines in cardiovascular. 2013, 216:T17-T36.
5.Tesauro M, Canale MP, Rodia G, Di Daniele N, Lauro D, Scuteri A, Cardillo CJCR, Practice: Metabolic syndrome, chronic kidney, and cardiovascular diseases: role of adipokines. 2011, 2011.
6.Smith Jr SCJTAjom: Multiple risk factors for cardiovascular disease and diabetes mellitus. 2007, 120:S3-S11.
7.Das UJN: Is obesity an inflammatory condition? 2001, 17:953–966.
8.Rifai N, Ridker PMJCoil: Inflammatory markers and coronary heart disease. 2002, 13:383–389.
9.Cozlea D, Farcas D, Nagy A, Keresztesi A, Tifrea R, Cozlea L, Carașca EJChsj: The impact of C reactive protein on global cardiovascular risk on patients with coronary artery disease. 2013, 39:225.
10.Flegal KM, Carroll MD, Ogden CL, Curtin LRJJ: Prevalence and trends in obesity among US adults, 1999–2008. 2010, 303:235–241.
11.Ginsberg HN, MacCallum PRJJotcs: The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. 2009, 4:113–119.
12.Després J-P, Lemieux I, Prud’Homme DJB: Treatment of obesity: need to focus on high risk abdominally obese patients. 2001, 322:716–720.
13.Nakamura K, Fuster JJ, Walsh KJJoc: Adipokines: a link between obesity and cardiovascular disease. 2014, 63:250–259.
14.Goldstein BJ, Scalia RJTJoCE, Metabolism: Adiponectin: a novel adipokine linking adipocytes and vascular function. 2004, 89:2563–2568.
15.Wattanapitayakul SK, Bauer JAJP, therapeutics: Oxidative pathways in cardiovascular disease: roles, mechanisms, and therapeutic implications. 2001, 89:187–206.
16.Jain S, Sharma S, Mandal T, Saxena MJP: Source apportionment of PM10 in Delhi, India using PCA/APCS, UNMIX and PMF. 2018, 37:107–118.
17.Flehmig G, Scholz M, Klöting N, Fasshauer M, Tönjes A, Stumvoll M, Youn B-S, Blüher MJPo: Identification of adipokine clusters related to parameters of fat mass, insulin sensitivity and inflammation. 2014, 9:e99785.
18.Coppack SWJPotNS: Pro-inflammatory cytokines and adipose tissue. 2001, 60:349–356.
19.Clément K, Langin DJJoim: Regulation of inflammation‐related genes in human adipose tissue. 2007, 262:422–430.
20.Slocum C, Kramer C, Genco CJJoim: Immune dysregulation mediated by the oral microbiome: potential link to chronic inflammation and atherosclerosis. 2016, 280:114–128.
21.Kim C, Park H, Kawada T, Kim J, Lim D, Hubbard N, Kwon B, Erickson KL, Yu RJIjoo: Circulating levels of MCP–1 and IL–8 are elevated in human obese subjects and associated with obesity-related parameters. 2006, 30:1347.
22.Wang H, Chu WS, Hemphill C, Elbein SCJTJoCE, Metabolism: Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. 2002, 87:2520–2524.
23.De Luis D, Sagrado MG, Conde R, Aller R, Izaola OJNh: Resistin levels and inflammatory markers in patients with morbid obesity. 2010, 25:630–634.
24.Park HK, Kwak MK, Kim HJ, Ahima RSJTKjoim: Linking resistin, inflammation, and cardiometabolic diseases. 2017, 32:239.
25.Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski AJTJoI: Resistin, an adipokine with potent proinflammatory properties. 2005, 174:5789–5795.
26.Deshmane SL, Kremlev S, Amini S, Sawaya BEJJoi, research c: Monocyte chemoattractant protein–1 (MCP–1): an overview. 2009, 29:313–326.
27.Carr MW, Roth SJ, Luther E, Rose SS, Springer TAJPotNAoS: Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. 1994, 91:3652–3656.
28.Bobryshev YVJM: Monocyte recruitment and foam cell formation in atherosclerosis. 2006, 37:208–222.
29.Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZJB, communications br: Human resistin stimulates the pro-inflammatory cytokines TNF-α and IL–12 in macrophages by NF-κB-dependent pathway. 2005, 334:1092–1101.
30.Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MAJPm: An inflammatory cascade leading to hyperresistinemia in humans. 2004, 1:e45.
31.Heinrich J, Schulte H, Schönfeld R, Köhler E, Assmann GJT, haemostasis: Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. 1995, 73:374–379.
32.Pietilä K, Harmoinen A, Hermens W, Simoons M, Van de Werf F, Verstraete MJEhj: Serum C-reactive protein and infarct size in myocardial infarct patients with a closed versus an open infarct-related coronary artery after thrombolytic therapy. 1993, 14:915–919.